SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 674.95+3.1%Nov 11 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: CuttingEdge Bio who wrote (2880)3/27/2020 10:25:08 PM
From: Miljenko Zuanic  Read Replies (1) of 3557
 
Abs binding to the distant epitope is not as potent as one binding to epitope on RBD, and blocking interaction with ACE2. However, epitopes on RBD undergone mutation and conformational changes (difference between SARS-CoV and nCoV, regardless it is the same receptor), making it difficult to be UNIQUE and UNIVERSAL.

IF pseudo-virus is lucking sequence and RBD-conformation needed for the triple-spike complex to bind ACE2, Abs from it my not be very effective. Deference between SARS and nCoV teach as what to expect from future viral variance, and possibly how to deal with it.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News